Experiments using a murine EGFR (mEGFR)-antagonistic antibody in a syngeneic preclinical model demonstrated that the anti-metastatic effect produced by treatment with this mab is mediated by T cells, since depletion of CD4+ and CD8+ T cells abrogated the anti-tumor effect (Garrido et al., 2007). This evidence concerns the gene EGFR and neoplasm.